LAUSR

and Clinical Study registry NIHIL (govTrial no: NCT03199066). Basic characteristics are summarized in Table 1. The clinical outcomes of DA-EPOCH-R cohort were compared to 117 pts treated with RCHOP regimen from 2 centres where intensification approach is not introduced. We performed 1:1 matched-pair analysis including these criteria: aaIPI, age and performance status. Results: Median age was 56 years (range: 20–70). Median number of administered DA-EPOCH-R cycles was 6 (range, 1-6). Dose escalation to 3 dose level or above was feasible in 68% pts. The overall response/complete remissions were achieved in 92%/78% pts. At a median follow up of 2.3 years, the median overall survival (OS) and progression-free survival (PFS) had not been reached; estimated 3-year PFS and OS were 70% and 85%, respectively. Predictors of short PFS in univariate analysis were the presence of B symptoms (p=0.006) and increased beta-2-microglobulin level (p=0.034). Serious (CTCAE grade III/IV) infections occurred in 21.6% of pts. 11% pts developed other serious non-hematologic toxicity. No significant differences in PFS and OS were observed between DA-EPOCH-R vs. R-CHOP in the matched-pair analysis (Fig. 1). Estimated 3-year PFS and OS of pts treated with R-CHOP were 66% and 70%, respectively. Conclusion: The DA-EPOCH-R is an active and feasible treatment for high risk DLBCL pts. According to our data, DA-EPOCH-R did not improve PFS or OS compared to standard R-CHOP treatment. Financial Support: This work was supported by the research project PROGRES Q40/08 and by a grant AZV 16-31092A from the Internal Grant Agency of the Czech Ministry of Health.